[HTML] sciencedirect.com

[HTML][HTML] 'Off-the-shelf'immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes

M Ando, H Nakauchi - Experimental hematology, 2017 - Elsevier
Highlights•Cytotoxic T lymphocytes (CTLs) exposed continuously to viral or tumor antigens
become exhausted.•Antigen-specific CTLs can be generated from iPSCs established from …
被引用次数：31 相关文章

'Off-the-shelf'immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.

M Ando, H Nakauchi - Experimental Hematology, 2016 - europepmc.org
Adoptive T-cell therapy to target and kill tumor cells shows promise and induces durable
remissions in selected malignancies. However, for most cancers, clinical utility is limited …
[HTML] exphem.org

[HTML][HTML] 'Off-the-shelf'immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes

M Ando, H Nakauchi - Experimental Hematology, 2017 - exphem.org
Adoptive T-cell therapy to target and kill tumor cells shows promise and induces durable
remissions in selected malignancies. However, for most cancers, clinical utility is limited …

'Off-the-shelf'immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes

M Ando, H Nakauchi - Experimental Hematology, 2017 - infona.pl
Adoptive T-cell therapy to target and kill tumor cells shows promise and induces durable
remissions in selected malignancies. However, for most cancers, clinical utility is limited …

[引用][C] 'Off-the-shelf'immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes

M Ando, H Nakauchi - Experimental Hematology, 2017 - cir.nii.ac.jp

'Off-the-shelf'immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes

M Ando, H Nakauchi - Experimental hematology, 2017 - pubmed.ncbi.nlm.nih.gov
Adoptive T-cell therapy to target and kill tumor cells shows promise and induces durable
remissions in selected malignancies. However, for most cancers, clinical utility is limited …